Add to ORKGThe proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosu
NZB/W F1 mice were treated with: 1) anti-CD20, 2) anti-CD20 plus bortezomib, 3) anti-CD20 plus anti-...
Background/Aims: Crucial steps in the initiation of lupus nephritis are the deposition of (auto-)ant...
NZB/W F1 mice were treated with: 1) anti-CD20, 2) anti-CD20 plus bortezomib, 3) anti-CD20 plus anti-...
Objectives To investigate whether bortezomib, a proteasome inhibitor approved for treatment of multi...
(immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nep...
Background and objectives (Immuno) proteasomes play a crucial role in processing of key proteins inv...
OBJECTIVE: To describe the pharmacodynamic monitoring of (immuno)proteasome inhibition following tre...
As treatment options in advanced systematic lupus erythematosus (SLE) are limited, there is an urgen...
Bortezomib, an inhibitor of proteasomes, has been reported to reduce autoantibody titers and to impr...
Abstract Background Bortezomib (Bz) is a proteasome inhibitor that directly targets antibody-produci...
Although the putative therapeutic options for patients with systemic lupus erythematosus (SLE) are s...
Bortezomib is a potent inhibitor of proteasomes currently used to eliminate malignant plasma cells i...
Anti-neutrophil cytoplasmic autoantibodies (ANCA) cause vasculitis and necrotizing crescentic glomer...
AbstractProteasome inhibition is a novel and promising strategy for the treatment of cancer. Bortezo...
Bortezomib is a proteasome inhibitor used for hematologic cancer treatment. Since it can suppress NF...
NZB/W F1 mice were treated with: 1) anti-CD20, 2) anti-CD20 plus bortezomib, 3) anti-CD20 plus anti-...
Background/Aims: Crucial steps in the initiation of lupus nephritis are the deposition of (auto-)ant...
NZB/W F1 mice were treated with: 1) anti-CD20, 2) anti-CD20 plus bortezomib, 3) anti-CD20 plus anti-...
Objectives To investigate whether bortezomib, a proteasome inhibitor approved for treatment of multi...
(immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nep...
Background and objectives (Immuno) proteasomes play a crucial role in processing of key proteins inv...
OBJECTIVE: To describe the pharmacodynamic monitoring of (immuno)proteasome inhibition following tre...
As treatment options in advanced systematic lupus erythematosus (SLE) are limited, there is an urgen...
Bortezomib, an inhibitor of proteasomes, has been reported to reduce autoantibody titers and to impr...
Abstract Background Bortezomib (Bz) is a proteasome inhibitor that directly targets antibody-produci...
Although the putative therapeutic options for patients with systemic lupus erythematosus (SLE) are s...
Bortezomib is a potent inhibitor of proteasomes currently used to eliminate malignant plasma cells i...
Anti-neutrophil cytoplasmic autoantibodies (ANCA) cause vasculitis and necrotizing crescentic glomer...
AbstractProteasome inhibition is a novel and promising strategy for the treatment of cancer. Bortezo...
Bortezomib is a proteasome inhibitor used for hematologic cancer treatment. Since it can suppress NF...
NZB/W F1 mice were treated with: 1) anti-CD20, 2) anti-CD20 plus bortezomib, 3) anti-CD20 plus anti-...
Background/Aims: Crucial steps in the initiation of lupus nephritis are the deposition of (auto-)ant...
NZB/W F1 mice were treated with: 1) anti-CD20, 2) anti-CD20 plus bortezomib, 3) anti-CD20 plus anti-...